QQQ   444.67 (-0.04%)
AAPL   170.70 (-1.51%)
MSFT   421.05 (-0.09%)
META   489.25 (-0.93%)
GOOGL   150.85 (-0.01%)
AMZN   180.85 (+0.57%)
TSLA   176.85 (-1.66%)
NVDA   908.44 (+0.66%)
NIO   4.61 (-1.28%)
AMD   181.43 (+1.02%)
BABA   72.45 (+1.20%)
T   17.57 (+0.11%)
F   13.24 (+1.38%)
MU   118.28 (-0.72%)
CGC   9.28 (-2.83%)
GE   175.02 (-2.83%)
DIS   122.68 (+1.41%)
AMC   3.75 (-13.59%)
PFE   27.91 (+0.47%)
PYPL   66.84 (+0.41%)
XOM   115.46 (+0.43%)
QQQ   444.67 (-0.04%)
AAPL   170.70 (-1.51%)
MSFT   421.05 (-0.09%)
META   489.25 (-0.93%)
GOOGL   150.85 (-0.01%)
AMZN   180.85 (+0.57%)
TSLA   176.85 (-1.66%)
NVDA   908.44 (+0.66%)
NIO   4.61 (-1.28%)
AMD   181.43 (+1.02%)
BABA   72.45 (+1.20%)
T   17.57 (+0.11%)
F   13.24 (+1.38%)
MU   118.28 (-0.72%)
CGC   9.28 (-2.83%)
GE   175.02 (-2.83%)
DIS   122.68 (+1.41%)
AMC   3.75 (-13.59%)
PFE   27.91 (+0.47%)
PYPL   66.84 (+0.41%)
XOM   115.46 (+0.43%)
QQQ   444.67 (-0.04%)
AAPL   170.70 (-1.51%)
MSFT   421.05 (-0.09%)
META   489.25 (-0.93%)
GOOGL   150.85 (-0.01%)
AMZN   180.85 (+0.57%)
TSLA   176.85 (-1.66%)
NVDA   908.44 (+0.66%)
NIO   4.61 (-1.28%)
AMD   181.43 (+1.02%)
BABA   72.45 (+1.20%)
T   17.57 (+0.11%)
F   13.24 (+1.38%)
MU   118.28 (-0.72%)
CGC   9.28 (-2.83%)
GE   175.02 (-2.83%)
DIS   122.68 (+1.41%)
AMC   3.75 (-13.59%)
PFE   27.91 (+0.47%)
PYPL   66.84 (+0.41%)
XOM   115.46 (+0.43%)
QQQ   444.67 (-0.04%)
AAPL   170.70 (-1.51%)
MSFT   421.05 (-0.09%)
META   489.25 (-0.93%)
GOOGL   150.85 (-0.01%)
AMZN   180.85 (+0.57%)
TSLA   176.85 (-1.66%)
NVDA   908.44 (+0.66%)
NIO   4.61 (-1.28%)
AMD   181.43 (+1.02%)
BABA   72.45 (+1.20%)
T   17.57 (+0.11%)
F   13.24 (+1.38%)
MU   118.28 (-0.72%)
CGC   9.28 (-2.83%)
GE   175.02 (-2.83%)
DIS   122.68 (+1.41%)
AMC   3.75 (-13.59%)
PFE   27.91 (+0.47%)
PYPL   66.84 (+0.41%)
XOM   115.46 (+0.43%)
NASDAQ:FEMY

Femasys (FEMY) Stock Price, News & Analysis

$1.60
+0.13 (+8.84%)
(As of 11:14 AM ET)
Today's Range
$1.44
$1.65
50-Day Range
$0.75
$2.22
52-Week Range
$0.25
$4.75
Volume
233,079 shs
Average Volume
707,658 shs
Market Capitalization
$34.64 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.67

Femasys MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
566.7% Upside
$10.67 Price Target
Short Interest
Bearish
5.61% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.31mentions of Femasys in the last 14 days
Based on 11 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.93) to ($0.74) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.46 out of 5 stars

Medical Sector

499th out of 939 stocks

Medical Instruments & Supplies Industry

1st out of 1 stocks

FEMY stock logo

About Femasys Stock (NASDAQ:FEMY)

Femasys Inc., a biomedical company, develops novel solutions for women's healthcare market in the United States and internationally. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. In addition, the company provides non-surgical product technologies. It offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.

FEMY Stock Price History

FEMY Stock News Headlines

Buy Friday, Sell Monday, No Exceptions
Every week traders grind it out Monday through Friday… But neglect trading Friday to Monday… Or… “over the weekend” As one professional trader explains, trading over the weekend is one of the most forgiving strategies you can use today. It allows him to sidestep a lot of the midweek volatility. Yet, gives him the opportunity to target some of the markets biggest stock moves. Just recently, he posted a trade on Nordstrom… The trade was published at 3pm on a Friday afternoon and by Monday morning the trade more than doubled.
Chardan Capital Reiterates Buy Rating for Femasys (NASDAQ:FEMY)
Femasys' (FEMY) "Buy" Rating Reaffirmed at HC Wainwright
Femasys (NASDAQ:FEMY) PT Raised to $10.00 at Jonestrading
Altcoin FRENZY Alert…
Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days…
Femasys Discloses Positive Data from FemaSeed Trial
Femasys Stock (NASDAQ:FEMY), Short Interest Report
See More Headlines
Receive FEMY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Femasys and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
3/27/2024
Next Earnings (Estimated)
4/04/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:FEMY
Fax
N/A
Employees
34
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.67
High Stock Price Target
$12.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+625.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-11,390,000.00
Net Margins
-1,164.78%
Pretax Margin
-1,164.23%

Debt

Sales & Book Value

Annual Sales
$1.21 million
Book Value
$1.29 per share

Miscellaneous

Free Float
18,102,000
Market Cap
$31.83 million
Optionable
Not Optionable
Beta
-2.95
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Ms. Kathy Lee-Sepsick (Age 56)
    Founder, President, CEO & Director
    Comp: $453.58k
  • Mr. Dov Elefant (Age 57)
    Chief Financial Officer
    Comp: $355.72k
  • Mr. Daniel Scott Currie (Age 60)
    COO, Senior VP & Secretary
    Comp: $352.55k
  • Ms. Mary An Merchant J.D.
    Ph.D., Vice President of Counsel & Intellectual Property
  • Dr. Jeffrey Marcus M.D.
    M.S., Chief Medical Advisor
  • Ms. Christine Thomas (Age 51)
    Senior VP of Regulatory & Clinical Affairs
  • Dr. James H. Liu M.D.
    Chief Medical Officer
  • Mr. Richard Spector
    Chief Commercial Officer

FEMY Stock Analysis - Frequently Asked Questions

Should I buy or sell Femasys stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Femasys in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" FEMY shares.
View FEMY analyst ratings
or view top-rated stocks.

What is Femasys' stock price target for 2024?

3 brokerages have issued 1-year price objectives for Femasys' stock. Their FEMY share price targets range from $10.00 to $12.00. On average, they expect the company's stock price to reach $10.67 in the next year. This suggests a possible upside of 566.7% from the stock's current price.
View analysts price targets for FEMY
or view top-rated stocks among Wall Street analysts.

How have FEMY shares performed in 2024?

Femasys' stock was trading at $0.9750 at the beginning of 2024. Since then, FEMY stock has increased by 64.1% and is now trading at $1.60.
View the best growth stocks for 2024 here
.

Are investors shorting Femasys?

Femasys saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 1,120,000 shares, an increase of 124.1% from the February 29th total of 499,700 shares. Based on an average daily trading volume, of 680,100 shares, the short-interest ratio is presently 1.6 days. Currently, 5.6% of the shares of the company are short sold.
View Femasys' Short Interest
.

When is Femasys' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024.
View our FEMY earnings forecast
.

How were Femasys' earnings last quarter?

Femasys Inc. (NASDAQ:FEMY) issued its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.19) earnings per share for the quarter, missing analysts' consensus estimates of ($0.15) by $0.04. The company had revenue of $0.27 million for the quarter. Femasys had a negative trailing twelve-month return on equity of 100.01% and a negative net margin of 1,164.78%.

When did Femasys IPO?

Femasys (FEMY) raised $35 million in an IPO on Friday, June 18th 2021. The company issued 2,700,000 shares at $12.00-$14.00 per share. Chardan and JonesTrading acted as the underwriters for the IPO.

Who are Femasys' major shareholders?

Femasys' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (0.72%), Vanguard Group Inc. (0.72%) and Northern Trust Corp (0.36%).
View institutional ownership trends
.

How do I buy shares of Femasys?

Shares of FEMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:FEMY) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners